Senescence is a cellular stress response characterized by persistent cell growth arrest under various stress conditions, including oncogene activation or tumor suppressor loss, which functions as a critical barrier that must be overcome to allow the progression from a precancerous or preinvasive lesion to a malignant tumor. Trefoil factor 1 (TFF1) is a secreted protein involved in maintaining the gastrointestinal epithelium by serving a tumor-suppressive role; however, TFF1 is overexpressed in several types of cancers. Here we report that TFF1 acts as a promoter of tumorigenesis in the context of prostate and pancreatic cancers by suppressing oncogene-induced senescence (OIS). Expression of TFF1 allows human prostate epithelial cells to escape OIS caused by the activated Ras oncogene or by reduced expression of the tumor suppressor PTEN, in part by the involvement of the EGF receptor-mediated pathway and inhibition of the expression of the cell cycle regulator p21. Without intrinsic promitogenic activity TFF1 may act in both autocrine and paracrine manners to enable cells to undergo the initial transformation and expansion against the restrictive microenvironment during early stage tumorigenesis. Taken together, our findings identify TFF1 as a soluble factor designed to act mainly to antagonize the OIS process to accelerate tumorigenesis.
prostate cancer C ellular senescence, or irreversible cellular growth arrest, was first identified after fibroblasts were allowed to undergo prolonged proliferation in culture (1) . Subsequent studies found that many types of cellular stress, including DNA damage, telomere dysfunction, oxidative damage, and chemotherapeutic drug treatment, could induce cellular senescence (2) . Expression of activated oncogenes such as Ras or loss of tumor suppressor genes such as PTEN also promotes senescence that acts as a barrier against malignant transformation in vivo (3) (4) (5) . This type of senescence, known as oncogene-induced senescence (OIS), differs from other stress-induced senescence and is a potentially tumor-suppressive mechanism functioning in addition to other well-defined mechanisms including apoptosis (4) (5) (6) (7) (8) . OIS acts as an initial defense against tumorigenesis by preventing cells with mutations from progressing through the cell cycle, thus limiting uncontrolled proliferation (9) . Although senescence was first illustrated in vitro, it has been hypothesized that, in the context of tumor formation, senescent cells, along with apoptotic cells, are more abundant in premalignant neoplastic lesions than in malignant tumors (2) . Epithelial cells, to progress through the tumorigenic process to a more malignant state, must successfully overcome the barriers of both senescence and apoptosis. Recently, it has been reported that cells within premalignant lesions secrete certain chemokines to promote and maintain OIS (10) (11) (12) (13) , limiting tumorigenic potential; however, given that preneoplastic lesions frequently progress to malignant tumors, it is highly likely that these signaling pathways become disrupted or that other signaling pathways may function to allow precancerous cells to overcome OIS.
As a member of the trefoil factor family (TFF) of proteins, TFF1 (pS2) is a 9-kDa mucin-associated secreted protein expressed in the gastrointestinal (GI) tract mucosa that is characterized by a 38-to 39-amino-acid trefoil domain containing six cysteine residues that form a cloverleaf disulfide structure (14) . This structure renders the protein acid-and protease-resistant, allowing it to function as a tumor suppressor in the harsh environment of the GI tract (15, 16) by stimulating restitution of damaged tissue associated with ulceration and inflammation to reduce tumor formation (17, 18) . Interestingly, TFF1 was shown to be overexpressed in tumor tissues from various organs where it is not normally expressed, including the pancreas (Table 1 ) and the prostate (Table 2) , although its functional significance remains unclear. To address this, we investigated the function of TFF1 in the context of prostate and pancreatic tumorigenesis and found that this secreted protein acts to suppress OIS. Although the signaling pathway by which TFF1 functions to counter the senescence process remains largely unclear, EGF receptor (EGFR) activity and the cell cycle regulator p21 appear to play a critical role. Taken together, our results indicate that in prostate and pancreatic cancer, the previously defined tumor suppressor TFF1 promotes tumorigenesis by enabling precancerous lesions to overcome the barrier of OIS.
Results

TFF1 Expression
Is Up-Regulated in Pancreatic and Prostate Cancer. A large number of studies indicate that TFF1 expression is absent or occurs at low levels in nonmalignant pancreatic and prostate tissues. Elevated expression levels of TFF1 are frequently observed in pancreatic and prostate malignancies (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) , suggesting that TFF1 may be involved in the tumorigenesis of these cancers. These data are not, however, sufficiently convincing because of the lack of strict statistical analysis in some studies and the reduced statistical power in others with small sample sizes. We performed a systematic review of all published studies analyzing expression of TFF1 in nonmalignant or malignant tissues of the pancreas and prostate. In pancreatic cancer, positive expression of TFF1, detected by immunohistochemistry (IHC), Northern blot, or RT-PCR, was consistently reported by independent studies to occur more frequently in malignant pancreatic tissues compared with nonmalignant tissues. Compared with only 7.3% of normal tissues, 74.1% of the tumor samples tested positive for TFF1 expression (P < 0.001, Table 1 ). In prostate cancer, differences in the overall relative frequencies of positive TFF1 expression between nonmalignant and malignant tissues were not as large as those in pancreatic cancer (24.5% vs. 60.8%); however, this difference was still found to be highly statistically significant (χ 2 = 65.2, P < 0.001, Table 2 ). Additionally, a previously reported microarray analysis indicated that TFF1 was upregulated ∼5.62-fold in pancreatic intraepithelial neoplasia (PanIN) lesions compared with normal duct epithelium (27) . These findings provide quantitative confirmation to our qualitative results. Together, these data indicate that TFF1 expression is elevated in both pancreatic and prostate cancers.
To investigate if TFF1 overexpression in prostate tumors was correlated with specific stages of cancer development, we performed IHC analysis on eight normal prostate tissue samples, two prostatic intraepithelial neoplasia (PIN) tissue samples that represent preinvasive lesions, and eight prostatic carcinoma tissue samples (Fig. S1 A and B) . Consistent with our meta-analysis, the proportion of TFF1-positive samples in those with malignancy (including PIN and carcinoma) was significantly higher compared with that in normal prostate tissue samples (70.0% vs. 0%, P = 0.004). Significant differences in TFF1 expression were also observed when comparing normal prostate to either PIN (0% vs. 100%, P = 0.022) or carcinoma (0% vs. 62.5%, P = 0.013). Although a slight decrease in the proportion of TFF1-positive cells was observed in the carcinoma samples (62.5%) compared with PIN samples (100%), this difference was not significant (P = 0.467). We also failed to find any correlation between TFF1 expression and Gleason score among the carcinoma samples (P = 1.00). We concluded that TFF1 is upregulated in prostatic cancer samples, but overexpression is not correlated with a specific cancer stage. Having confirmed the expression status of TFF1 in prostate cancer, we determined if TFF1 plays a role in tumorigenesis in the context of xenograft tumor formation. We screened a group of established human prostate and pancreatic cancer cell lines and found that many expressed various levels of TFF1 protein. We chose the PC3 prostate cancer cell line and the HS766T pancreatic cancer cell line for analysis by stably reducing the expression of TFF1 by shRNA-mediated knockdown. To avoid an off-target effect, we used two independent TFF1 shRNA constructs. In both cell lines, the shRNA-1 construct reduced TFF1 levels more efficiently than the shRNA-2 construct ( Fig. 1 A and B and Fig. S2 ). In direct correlation with the extent of TFF1 suppression, the number of viable cells from both cell lines was decreased proportionally to the degree of TFF1 knockdown ( Fig. 1 C and D) . We then determined the effect of TFF1 reduction on the formation of xenograft tumors when these cells were implanted s.c. in nude mice. There was a dramatic reduction in the size of tumors formed by the TFF1 knockdown cells compared with controls, indicating that TFF1 is essential for tumor growth ( Fig. 1 E and F) .
To determine if this phenotype could occur in cancer cells derived from GI tissues where this protein is normally expressed, we used our TFF1 shRNA constructs to reduce TFF1 levels in the human gastric cancer cell line Kato III (Fig. S3A) . In contrast to PC3 and HS766T cells, there was no significant change in cell viability between vector control (VC) and knockdown cells as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Fig. S3 B and C) . These data suggest that the observed effects are specific for prostate and pancreatic Meta-analysis reveals elevated TFF1 expression levels in malignant pancreatic and prostatic lesions that are not observed in the normal samples. IHC, immunohistochemistry; RT-PCR, reverse transcriptase PCR.
cancers and that TFF1 expression levels determine the degree of phenotypic changes.
Knockdown of TFF1 Results in Increased Senescence in Pancreatic and
Prostate Cancer Cells. The observed decreases in cell viability in vitro and tumor formation in vivo in the PC3 and HS766T cells could be the result of reduced cell proliferation, increased apoptosis, or senescence. To address this question, we performed cell cycle analysis on PC3 cells stably expressing the shRNA-2 construct or VC. Compared with the control cell line, there was an observable increase in the cell population in the sub-G1 phase of the cell cycle when TFF1 expression was decreased, with only a slight decrease in S-phase population detected ( Fig. 2A) . Similar results were obtained using HS766T cells stably expressing the shRNA constructs (Fig. 2B ). We next tested if TFF1 knockdown resulted in increased apoptosis. Using annexin-V staining, we detected lower levels of apoptosis in TFF1 knockdown PC3 cells compared with control ( Fig. 2C ), suggesting that apoptosis was not likely the underlying mechanism for the observed phenotype in cancer cells with reduced TFF1 expression.
While conducting cell cycle analysis, we noted that the morphology of many of the TFF1 knockdown PC3 and HS766T cells became greatly enlarged and flattened, resembling that of senescent cells. To determine if TFF1 reduction caused those cells to undergo senescence, we used β-galactosidase (β-gal) staining to quantify the differences in the control and knockdown cells under both normal and serum-starved conditions. A dramatic increase in the percentage of β-gal-positive cells was observed after TFF1 knockdown in both cell lines (Fig. 3 A and B) . To confirm TFF1 knockdown results in senescence, we used another pancreatic cancer cell line (Capan-1) stably infected with a different set of lentiviral-based shRNA constructs and observed a similar senescence phenotype (Fig. S4A) . Interestingly, it appears that senescence observed after TFF1 knockdown is specific for pancreatic and prostate cancer, as there was no difference in the level of β-gal staining between the control and the Kato III gastric cancer cells with decreased TFF1 expression (Fig. S4B) , again demonstrating the tissue-specific impact of TFF1 reduction.
To determine if the senescence phenotype observed in prostate and pancreatic cancer cells was primarily a consequence of reduced TFF1 expression, we added TFF1-conditioned media from PC3 cells to the PC3 TFF1 knockdown cells. We observed a partial rescue of the senescence phenotype in the TFF1 knockdown cells by the addition of conditioned media, suggesting that TFF1 HS766T cells stably expressing TFF1 or VC shRNA constructs were established and then stained for β-gal that was quantified by using microscopy. All error bars represent the results of three independent experiments (*P < 0.0001).
was likely the secreted factor preventing the cancer cells from senescing (Fig. S5) . ) by retroviral delivery that resulted in a flattened and enlarged cell morphology associated with senescence, as well as a large increase in β-gal staining (Fig. S6) . To avoid the potential complication of using conditioned media from established cancer cell lines that may contain unknown factors, we collected conditioned media from immortalized human PrEC infected with a retroviral vector with or without TFF1 and added the media to normal human PrEC infected with oncogenic H-Ras or VC. Addition of the conditioned media with or without TFF1 did not affect the status of those cells infected with the control virus in terms of the percentage of cells defined as senescent by β-gal staining (Fig. 4A ). There was, however, a significant reduction in the number of β-galpositive cells in the culture infected with H-Ras retrovirus when TFF1 is present compared with those without TFF1, suggesting that TFF1 could have a potent effect in preventing a large percentage of normal PrEC from entering OIS (Fig. 4A) .
Although the Ras-mediated signaling pathway is activated in many cancer types, activation mutations in the Ras gene are rare in prostate cancer. In contrast, the tumor suppressor PTEN is frequently lost in prostate cancer (32) . To mimic the biological process during which reduction in PTEN expression could lead to OIS in normal PrEC, we used an inducible lentiviral system to target the expression of PTEN. Doxycycline-induced reduction in PTEN expression led to a significant increase in cellular senescence of those cells as indicated by an increase in β-gal-positive cells (Fig. 4B) . Incubation of those cells with conditioned media containing TFF1 reduced this level of senescence to the basal state, again demonstrating the potent inhibitory effect of TFF1 on the ability of PTEN inactivation to induce senescence in normal PrEC (Fig. 4B) . To rule out the possibility that some unknown factor(s) other than TFF1 in the conditioned media could be responsible for the observed phenotype, we subsequently used recombinant TFF1 protein to repeat these experiments and confirmed that TFF1 is indeed the primary factor that could act to rescue the OIS phenotype (Fig. S7) .
EGFR Activity Is Required for TFF1 to Overcome OIS and Loss of TFF1 Expression Results in Increased Expression of the OIS Marker p21,
Required for Senescence Induced by TFF1 Knockdown. TFF1 is a secreted protein that likely exerts its effects through protein(s) anchored on the cell surface, but the molecular nature of its receptor remains elusive. To gain insight into this question, we took a candidate approach by examining the possible involvement of known signaling pathway(s) initiated by plasma membrane-bound receptors for growth factors for mediation of TFF1 activity in the context of overcoming OIS. In this regard, previous reports indicated that TFF1 and EGFR are co-overexpressed in certain malignant tumors and that TFF1 might exert its activity through EGFR, although no definitive signaling pathways have been elucidated (31) . To test if EGFR activity contributes to the ability of TFF1 to suppress OIS, we repeated the experiment using PrEC with Ras-induced OIS and recombinant TFF1 in the presence or absence of an EGFR inhibitor. As shown in Fig. 5A , TFF1 is unable to suppress the OIS phenotype in the presence of the EGFR inhibitor, indicating that EGFR activity is required for TFF1 to exert its antisenescence effect.
To further explore the molecular nature of the TFF1-signaling pathway in suppressing OIS, we examined changes in the expression status of genes that are likely involved in this process. We used an RT-PCR array to assess the expression profile of 84 genes involved in the regulation of the cell cycle using PC3 cells with or without the stable knockdown of TFF1 (Fig. S8A) . Among the candidate genes whose expression profile displayed significant changes due to the difference in TFF1 expression status (a partial list is shown in Fig. S8B) , we chose the cyclin-dependent kinase inhibitor p21 (CDKN1A or CIP1) for further analysis. We selected this candidate gene primarily because of its sevenfold increase at the mRNA level in TFF1 knockdown PC3 cells (Fig. 5B and Fig. S8B ) and its known function in maintaining senescence under conditions of oncogenic stress (33) . The observed change in p21 mRNA level was confirmed at the protein level using PC3 cells expressing either TFF1-targeting shRNA construct (Fig. 5C) . Additionally, cells transduced with shRNA constructs targeting both TFF1 and p21 displayed a significant reduction in senescence compared with PC3 cells transduced with TFF1 shRNA alone (Fig. 5D ). These results demonstrate a potent ability of TFF1 to suppress expression of p21, providing a potentially unique mechanism whereby TFF1 may allow cells to escape from OIS. In contrast to the status of p21, the protein expression profile of other well-defined senescence markers, such as p14 and p15, did not show any significant change (Fig. 5C) . Surprisingly, the protein level of p16, a cell cycle regulator often associated with cellular senescence, was dramatically decreased in the cells with reduced TFF1 expression (Fig. 5C) , a profile consistent with that of the RT-PCR results showing an approximately 2.7-fold decrease in p16 mRNA expression (Fig S8B) . A possible explanation for these findings is that p21-and p16-mediated senescence pathways can function independently, and p21 may play a role in early stage senescence with p16 functioning at a later stage (34) . Another possible explanation for our experimental results is that TFF1 also directly influences Ras-mediated cell growth and apoptosis pathways. To confirm that our results are specific to p21 function, we assayed HS766T cells that were transduced with scrambled control or TFF1 shRNA constructs for activation of common Ras pathway components. We observed no significant changes in the phosphorylation status of MEK, ERK, or AKT, indicating that Ras signaling is not altered by changes in TFF1 expression status (Fig S9) .
Discussion
Tumorigenesis in mammals is a complex multistep process consisting of genetic and epigenetic alterations that allow normal cells to progress into malignant variants that eventually become highly invasive tumors (35) . One of the barriers that inhibit the initial phase of the tumorigenic process is the induction of senescence in response to oncogene activation or loss of tumor suppressors. The notion that OIS is intimately associated with the tumorigenic process is strongly supported by a large body of in vivo evidence as senescence markers are detected in various types of precancerous lesions (11); however, the mechanisms associated with suppression of OIS and subsequent successful clonal expansion of cells that harbor oncogenic mutations remain largely unknown. In this regard, identification of TFF1 acting to counter the barrier of OIS represents a major step toward a better understanding of the molecular basis of the antisenescence process, because very few soluble factors have been reported to be functionally defined to act in a similar manner as TFF1 as an anti-senescence factor. Previous studies have shown that certain promitogenic growth factors and cytokines may display activities to counter the senescence process, primarily through promoting cell proliferation; however, several cytokines, such as interleukin 6, appear to play an opposite role because they are required for the execution and maintenance of OIS when they are produced by senescent fibroblasts in a cell-autonomous manner (11) . In contrast to those promitogenic growth factors, TFF1 does not exhibit a mitogenic activity when it is applied to normal prostate epithelial cells despite displaying a potent suppressive effect on OIS. In this sense, TFF1 may serve as a biomarker for the transition between the senescent state and precancerous/cancerous lesions because its presence would signal an initial breach of the OIS barrier during early tumorigenesis. This notion is supported by our IHC data showing that high TFF1 expression can be detected in early stage prostate carcinoma samples. Thus, TFF1 may be considered to be an example of an antisenescence factor that could play a critical role in overcoming the OIS barrier.
As a secreted protein, TFF1 may act in both autocrine and paracrine manners to enable the TFF1-producing and neighboring cells to undergo the genetic change-induced initial transformation and expansion process against the restrictive microenvironment. Although the mechanism by which TFF1 expression is aberrantly induced during the initiation of prostate or pancreatic lesions remains to be determined, it is likely that TFF1 may allow at least a subset of premalignant cells to avoid senescence and begin to acquire additional genetic and epigenetic changes to fully evolve into a cancerous state. To further test this postulation, we generated transgenic mice, which enabled the inducible expression of TFF1 in a tissue-specific manner to determine if the presence of TFF1 may accelerate tumorigenesis induced by activated Ras or deletion of PTEN. Using the same mouse model systems, we determined if TFF1 could additionally exert a positive effect on latestage tumorigenesis because our results indicated that even the metastatic prostate and pancreatic cancer cells examined in our study appear to require the production of TFF1 for xenograft tumor formation. This suggests that some tumors may become "addicted" to the presence of TFF1 to facilitate the protumorigenic functions of activated oncogenes by allowing the cells to bypass antitumorigenic mechanisms (36, 37) .
The physiological function of TFF1 in the lumen of the digestive tract is postulated to be that of a positive regulator for the restitution process following tissue injury such as ulceration (16) (17) (18) . TFF1 is secreted into the lumen in large quantity to help wound repair, and its activity may even be associated with inflammation. Reduced TFF1 expression or loss of the TFF1 gene leads to increased tumor formation, likely due to ineffective wound healing and chronic inflammation in the epithelial tissue exposed to the hash external environment of the gastrointestinal track (16) (17) (18) . In such a tissue context, TFF1 is functionally defined as a tumor suppressor; however, when TFF1 is abnormally overproduced in epithelial tissues of glandular organs, such as prostate and pancreas, it acts as a promoter of tumorigenesis, likely through its antisenescence activity. Thus, TFF1 represents another example of genes whose complex roles in tumorigenesis are manifested in a tissue-specific manner, although it remains to be determined if different intrinsic activities at the cellular and molecular level underlie the opposing activities of TFF1.
Although the signaling pathway by which TFF1 may exert its antisenescence effect remains to be fully elucidated, the activity of the EGFR-mediated pathway appears to be required by TFF1 to overcome the barrier of OIS, an observation consistent with a previous report that aberrant EGFR activity promotes tumor cell escape from OIS (38) . It remains to be determined, however, if TFF1 acts to suppress OIS through direct or indirect activation of EGFR and if the EGFR-signaling cascade represents a parallel pathway, the activity of which is required for TFF1 to function as an antisenescence factor. Regardless of the upstream signaling components, it is clear that TFF1 appears to inhibit the onset of OIS by potently repressing the expression of p21, one of several cyclin-dependent kinase CDK inhibitors that are known to be involved in the initiation of cellular senescence. This idea is further supported by our finding that knockdown of TFF1 does not result in high levels of senescence in cells where p21 is also knocked down. Interestingly, the expression of p16, a factor considered to be more uniformly involved in the maintenance of senescence, is increased by the presence of TFF1, whereas the expression of two other CDK inhibitors, p14 and p15, remains unchanged, suggesting complex roles played by this group of cell cycle regulators under specific cellular contexts. Further study will be required to delineate this pathway and provide insight into the mechanisms regulating tumor progression and maintenance in the presence of oncogenic stress.
Materials and Methods
Meta-analysis. Studies investigating the expression of TFF1 (pS2, pNR-2, HPS2, BCEI) in pancreatic and prostatic cancers were obtained from the PubMed database. Only reports studying TFF1 expression in the nonmalignant/malignant tissues of pancreas/prostate were analyzed. For ideal representation, reports studying extremely rare malignancies, such as neuroendocrine cancer, ampullary carcinoma, and pancreatic cystic neoplasm that together compose only <5% of all pancreatic cancer cases, were excluded from the analysis, and only studies of PanIN or PIN and adenocarcinomas were included. For the meta-analysis, only two categories were considered: nonmalignant (normal, benign, or non-neoplastic) and malignant (neoplastic and carcinomatous) tissues. For each category, frequency counts and relative frequencies of TFF1-positive or -negative samples, evaluated by IHC, Northern blot, or RT-PCR, were extracted from each individual study. Frequency counts between nonmalignant and malignant tissues were compared for each individual or the combined study population, with the statistical significance of the difference being examined using the Fisher's exact (one-sided) test or the χ 2 test where appropriate. P values of 0.05 or less were considered statistically significant. All statistical computations were performed with the statistical software package SAS9.2.
Plasmids. TFF1 cDNA was amplified from HS766T cells and cloned into a pBabe-puro vector (39) . Retroviral vectors encoding TFF1 shRNAs were generated by cloning oligonucleotide sequences into the pSUPER retro-puro vector (40 
